shRNA-modified CD34+ cell therapy / Kanglin Biotech - LARVOL DELTA

An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients. (clinicaltrials.gov) - P1; N=6; Recruiting; Sponsor: Shanghai Public Health Clinical Center; Trial completion date: Jan 2020 ➔ Dec 2020; Trial primary completion date: Jul 2018 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date